Regarding gastroesophageal cancer, multiple studies currently are focused on blocking the PD1 pathway.39–42 One of these studies is the recently started phase 3 clinical trial with nivolumab treatment for patients with unresectable advanced or recurrent gastric cancer, including gastroesophageal junction cancer (ONO-4538-12). This evidence concerns the gene PDCD1 and gastric cancer.